research and clinical trials

Strathfield Retina Clinic has a strong commitment to clinical research and actively supports new and innovative treatments for retinal diseases. Our dedicated research unit is currently involved in a number of international clinical trials and programs involving patients with Age-Related Macular Degeneration, Diabetic Macular Oedema and Retinal Vein Occlusions. These studies are pivotal in quantifying the outcomes of current management and support the potential for future treatments.

The practice has a wide-range of experience in clinical trials and recognise the importance of research to promote understanding of eye disorders, investigate new therapeutic agents and advise patients on the best available treatment options.

Some patients enrolled in trials have the benefit of accessing new and advanced treatments during the final stages of development, prior to market release.

current clinical trials:

A Phase III study evaluating the safety and efficacy of Faricimab in myopic CNV

  • Inclusion: 18yrs old+, Treatment naive myopic CNV, VA 6/12-6/95, AXL >26.0mm, Myopia -6D or worse

  • Exclusion: Previous intravitreal injections, laser, vitrectomy, glaucoma surgery, corneal transplant. Presence of ocular inflammation, CSR, schisis, ERM, previous retinal tear

POYANG

RECRUITING

A Phase III study of KHK4951 eyedrops to explore safety and efficacy in the treatment of wet age related macular degeneration

  • Inclusion: 50yrs old+, treatment naive or previously treated AMD <3years from diagnosis with active leakage at the fovea. VA 6/9.5-6/60, CST <450um, BP under 150/100

  • Exclusion: AntiVEGF within 12 weeks, History of stroke / TIA / blood clots / bleeding disorders. Previous macular laser, PDT laser, glaucoma surgery, corneal transplant. Subretinal hemorrhage / fibrosis / atrophy that involves the fovea.

Kk amd

Recruiting

A Phase III study of KHK4951 eyedrops to explore safety and efficacy in the treatment of diabetic macula oedema

  • Inclusion: 18yrs old+, treatment naive or previously treated DMO <3 years from diagnosis, VA 6/9.5-6/60, CST 325um-500um, Hba1c <11%, BP <140/90

  • Exclusion: AntiVEGF within 12 weeks, History of stroke / TIA / blood clots / bleeding disorders. Proliferative diabetic retinopathy. Previous macular laser, PDT laser, glaucoma surgery, corneal transplant.

KK DMO

Recruiting

A phase III study of Tinlarebant to explore safety and efficacy in the treatment of geographic atrophy (GA)

  • Inclusion: 60-85 yrs old, VA 6/24 or better, GA lesion 1-10mm^2 (foveal involvement <1.25mm^2 in either eye) BMI <40, HBa1c <8%

  • Exclusion: Presence of DMO, macular disease or other retinal vascular conditions, Medications containing Vitamin A or Retinoids that can’t be stopped.

PHOENIX

RECRUITING

A phase IIb study of intravitreal gene therapy treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

  • Inclusion: 60yrs old+, GA lesion 2.5-17.5mm^2 (non subfoveal), VA 6/45 or better,

  • Exclusion: Previous CNV, presence of diabetic retinopathy, CSR, retinal vascular disease, macular hole, macular fibrosis. Previous macular laser, PDT laser, vitrectomy, glaucoma surgery, corneal transplant.

PARASOL

RECRUITING

Treat & Extend versus Fixed dosing with Faricimab for management of Diabetic Macular Oedema (DMO)

  • Inclusion: Foveal involving DMO, CST >325um, VA 6/7.5-6/120. Hba1c <10%

  • Exclusion: Previous macular laser, antiVEGF within 12 weeks, DMO persisting for more than 2 years.

INSITE

RECRUITING

Assessing the efficacy and durability of intravitreal Faricimab in patients currently treated for neovascular age-related macular degeneration (nAMD)

  • Inclusion: CNV diagnosed <3 years ago, most recent treatment within last 3 months, active CNV affecting central subfield, VA 6/120 or better

  • Exclusion: Presence of geographic atrophy / fibrosis, vitreous hemorrhage.

FURGGHORN

RECRUITING

A phase III study of the efficacy and safety of Aflibercept 8 mg in Macular Oedema secondary to Retinal Vein Occlusion

QUASAR

RECRUITMENT CLOSED

A phase III, multicentre, double-masked, randomised study to evaluate the efficacy and safety of Intravitreal OPT-302 in combination with Aflibercept, compared with Aflibercept alone, in participants with neovascular age-related macular degeneration (nAMD)

cOAST

RECRUITMENT CLOSED

A phase III, open-label, multicenter, Oaks extension study to evaluate the long-term safety and efficacy of Pegcetacoplan in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

GALE

RECRUITment closed

A phase II, double-masked, placebo-controlled, dose range finding study of Danicopan in patients with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD)

ONWARD

RECRUITMENT CLOSED